Pathogenetic features of the hepatobiliary system damage in patients with metabolic syndrome

Cover Page

Cite item

Full Text

Abstract

A review of articles covering the modern views on the hepatobiliary system damage features in patients with clinical manifestations of metabolic syndrome. 196 original papers published over the last 6 years were found using PubMed, MEDLINE, E-library databases, from which 50 articles were picked out for the review. Considering high prevalence of metabolic syndrome, the studied problem seems important. The influence of obesity and associated insulin resistance at launching the systemic inflammation leading to activation of immunological cascade resulting in terget organs damage in such patients is highlighted. The pathogenesis of liver, gall bladder and bile ducts damage at presence of metabolic disorders is outlined. The role of inflammatory and anti-inflammatory cytokines in liver tissue damage is described. Based on the data of literature review and own data, it was shown that the lipid metabolism alterations are associated with liver functional damage, and liver in patients with metabolic syndrome is not only participating in atherogenic dislipoproteinemia development, but also damaged as the target organ. It was revealed that the key link in the gall bladder pathology in patients with metabolic syndrome is the lipid metabolism alterations that lead to the excess cholesterol bile excretion and cholesterol monohydrate crystals sedimentation. It was also shown that the functionally affected hepatocytes produce imperfect bile micelles with high cholesterol and low phospholipid levels, increasing the bile lithogenicity. High bile cholesterol level stimulating the mucin secretion by gall bladder wall, which is the important component of bile sediment and increases the bile crystalloids aggregation.

About the authors

O V Gaus

Omsk State Medical Academy, Omsk, Russia

Email: gaus_olga@bk.ru

V A Akhmedov

Omsk State Medical Academy, Omsk, Russia

References

  1. Ахмедов В.А., Керученко А.Л. Участие цитокинов в механизмах формирования неалкогольной жировой болезни печени // Вестн. НГУ. Серия: Биология, клиническая медицина. — 2012. — Т. 10, вып. 1. — С. 76–80.
  2. Гаусс О.В., Ахмедов В.А. Иммунологические параллели в течении метаболического синдрома, ассоциированного с желчнокаменной болезнью // Фундамент. исслед. — 2013. — Т. 7, №1. — С. 51–54.
  3. Гаусс О.В., Ахмедов В.А. Клинико-биохимические и иммунологические особенности желчнокаменной болезни, ассоциированной с метаболическим синдромом // Вестн. НГУ. Серия: Биология, клиническая медицина. — 2013. — Т. 11, №3. — С. 125–129.
  4. Диагностика и лечение неалкогольной жировой болезни печени: методические рекомендации для врачей / Под ред. В.Т. Ивашкина. — М.: МЕДпресс-информ, 2012. — 32 с.
  5. Ивашкин В.Т., Маевская М.В. Липотоксичность и метаболические нарушения при ожирении // Рос. ж. гастроэнтерол. гепатол. колопроктол. — 2010. — №1. — С. 4–13.
  6. Ильченко А.А., Долгашева Г.М. Ожирение как фактор риска неалкогольной жировой болезни жёлчного пузыря (холецистостеатоза, стеатохолецистита) // Эксперим. и клин. гастроэнтерол. — 2009. — №8. — С. 80–93.
  7. Лазебник Л.Б., Звенигородская Л.А. Метаболичес­кий синдром и органы пищеварения. — М.: Анахарсис, 2009. — 184 с.
  8. Лазебник Л.Б., Звенигородская Л.А., Егорова Е.Г., Мельникова Н.В. Неалкогольная жировая болезнь печени при дислипидемии и инсулинорезистентности: сходство и различия; дифференцированный подход к терапии // Эксперим. и клин. гастроэнтерол. — 2009. — №8. — С. 4–11.
  9. Оганов Р.Г., Мамедов М.Н., Колтунова И.А. Метаболический синдром: путь от научной концепции до клинического диагноза // Врач. — 2007. — №3. — С. 3–7.
  10. Abdul-Ghani M.A., De Fronzo R.A. Pathogenesis of insulin resistance in skeletal muscle // J. Biomed. Biotechnol. — 2010. — Vol. 47. — P. 62–79.
  11. Ahonen T.M., Saltevo J.T., Kautiainen H.J. et al. The association of adiponectin and low-grade inflammation with the course of metabolic syndrome // Nutr. Metab. Cardiovasc. Dis. — 2012. — Vol. 22. — P. 285–291.
  12. Angulo P.A. Nonalcoholic fatty liver disease // N. Engl. J. Med. — 2007. — Vol. 346. — P. 1221–1231.
  13. Ata N., Kucukazman M., Yavus B. et al. The metabolic syndrome is associated with complicated gallstone dise­ase // Can. J. Gastroenterol. — 2011. — Vol. 25. — P. 274–276.
  14. Baffy G., Brunt E.M., Caldwell S.H. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace // J. Hepatol. — 2012. — Vol. 56. — P. 1384–1391.
  15. Baranova A., Priyanka L., Birerdinc A., Younossi Z. Non-invasive markers for hepatic fibrosis // BMC Gastroenterology. — 2011. — Vol. 11. — P. 3–15.
  16. Biddinger S.B., Haas J.T., Yu B.B. et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones // Nat. Med. — 2008. — Vol. 14. — P. 778–782.
  17. Bradley J.R. TNF-mediated inflammatory disease // J. Pathol. — 2008. — Vol. 214. — P. 149–160.
  18. Byrne C.D. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management // Diabet Med. — 2012. — Vol. 29. — P. 98–107.
  19. Caldwell S., Argo C. The natural history of non-alcoholic fatty liver disease // J. Dig. Dis. — 2010. — Vol.28. — P. 162–168.
  20. Dain A., Repossi G., Das U.N., Eynard A.R. Role of PUFAs, the precursors of endocannabioids, in human obesity and type 2 diabetes // Front Biosci. (Elite Ed). — 2010. — Vol. 2. — P. 1432–1447.
  21. Dodson M.V., Mir P.S., Hausman G.J. et al. Obesity, metabolic syndrome, and adipocytes // J. Lipids. — 2011. — Vol. 7. — P. 72–86.
  22. Duvnjak L., Duvnjak M. The metabolic syndrome — an ongoing story // J. Physiol. Pharmacol. — 2009. — Vol. 60, suppl. 7. — P. 19–24.
  23. Fierbinteanu-Braticevici C., Dina I., Petrisor A. et al. Noninvestigations for nonalcoholic fatty liver disease and liver fibrosis // World J. Gastroenterology. — 2010. — Vol. 16. — P. 4784–4791.
  24. Fierbinteanu-Braticevici C., Negreanu L., Tarantino G. Is fatty liver always benign and should not consequently be treated // J. Physiol. Pharm. — 2013. — Vol. 64. — P. 3–9.
  25. Galic S., Oakhill J.S., Steinberg G.R. Adipose tissue as an endocrine organ // Mol. Cell Endocrinol. — 2010. — Vol. 316. — P. 129–139.
  26. Garcia-Galiano D., Sanchez-Garrido M.A., Espejo I. et al. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obesepatients // Obesity Surgery. — 2007. — Vol. 17. — Р. 493–503.
  27. Hallmans G., Edlinger M., Stocks T. et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults // Int. J. Cancer. — 2012. — Vol. 131. — P. 193–200.
  28. Jarrar M.H., Baranova A., Collantes R. et al. Adipokines and cytokines in non-alcoholic fatty liver disease // Aliment. Pharmacol. Therap. — 2008. — Vol. 27. — Р. 412–421.
  29. Jiang J., Torok N. Non-alcoholic steatohepatitis and the metabolic syndrome // Metab. Synd. Relat. Dis. — 2008. — Vol. 3. — P. 1–7.
  30. Lapice E., Maione C., Patti L. et al. Abdominal adiposity is associated with elevated C-reactive protein independent of BMI in healthy nonobese people // J. Diabetes Care. — 2009. — Vol. 32. — P. 1734–1736.
  31. Larsson S.C., Wolk A. Obesity and the risk of gallbladder cancer: a meta-analysis // Br. J. Cancer. — 2007. — Vol. 96. — P. 1457–1461.
  32. Lassailly G., Caiazzo R., Hollebecqueetal A. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity // Eur. J. Gastroenterol. Hepatol. — 2011. — Vol. 23. — P. 499–506.
  33. Lorenzo M., Fernandez-Veledo S., Vila-Bedmar R. et al. Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown adipocytes // J. Anim. Sci. — 2008. — Vol. 86, suppl. 14. — P. 94–104.
  34. Mendez-Sanchez N., Chavez-Tapia N.C., Motola-Kuba D. et al. Metabolic syndrome as a risk factor for gallstone disease // J. Gastroenterol. — 2005. — Vol. 11, N 11. — P. 1653–1657.
  35. Neuschwander-Tetri B.A. Nonalcoholic staetohepatitis: summary of an AASLD Single Topic Conference // J. Hepatology. — 2008. — Vol. 37. — P. 1202–1219.
  36. Pitt H.A. Hepato-pancreato-biliary fat: the good, the bad, the ugly // Informa Healthcare. — 2007. — Vol. 9. — P. 92–97.
  37. Popa C., Netea M.G., Riel P.L. et al. The role of TNF-α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk // J. Lipid Res. — 2007. — Vol. 48. — P. 751–762.
  38. Rahman R., Hammoud G.M., Almashhrawi A.A. et al. Primary hepatocellular carcinoma and metabolic syndrome: an update // World J. Gastrointestinal Oncology. — 2013. — Vol. 5. — P. 186–194.
  39. Reynaert H., Geerts A., Henrion J. The treatment of non-alcoholic steatohepatitis with thiazolidinediones // Aliment. Pharmacol. Ther. — 2005. — Vol. 22. — P. 897–905.
  40. Rodriguez-Hernandez H., Simental-Mendia L.E., Rodriguez-Ramirez G., Reyes-Romero M.A. Obesity and inflammation: epidemiology, risk factors, and markers of inflammation // Int. J. Endocrinology. — 2013. — Vol. 3. — P. 1–11.
  41. Schattenberg J.M., Schuppan D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic // J. Curr. Opin. Lipidol. — 2011. — Vol. 22. — P. 479–488.
  42. Silvera L.S., Monteiro P.A., Antunes B.M. et al. Intra-abdominal fat is related to metabolic syndrome and non-alcoholic fat liver disease in obese youth // BMC Pediatrics. — 2013. — Vol. 13. — P. 2–6.
  43. Sotornik R. Adipose tissue blood flow and metabolic syndrome // Cas. Lek. Cesk. — 2010. — Vol. 149. — Р. 155–159.
  44. Souza M.R., Diniz Mde F., Medeiros-Filho J.E., Araujo M.S. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease // Arq. Gastroenterol. — 2012. — Vol. 49. — P. 89–96.
  45. Speliotes E.K., Massaro J.M., Hoffmann U. et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study // Hepatology. — 2010. — Vol. 51. — P. 1979–1987.
  46. Stinton L.M., Shaffer E.A. Epidemiology of gallbladder disease: cholelithiasis and cancer // Gut and Liver. — 2012. — Vol. 6. — P. 172–187.
  47. Sundaresan S., Vijayagopal P., Mills N. et al. A mouse model for nonalcoholic steatohepatitis // J. Nutr. Biochem. — 2011. — Vol. 22. — Р. 979–984.
  48. Tarantino G., Finelli C. What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome // World J. Gastroenterol. — 2013. — Vol. 19. — P. 3375–3384.
  49. Yener O., Aksoy F., Demir M. et al. Gallstones associated with nonalcoholic steatohepatitis (NASH) and metabolic syndrome // Turk. J. Gastroenterol. — 2010. — Vol. 21. — P. 411–415.
  50. Yet J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance // Int. J. Obes. (Lond.). — 2009. — Vol. 33. — P. 54–66.

© 2014 Gaus O.V., Akhmedov V.A.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.





This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies